Status: Recruiting
Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
This is a multicenter, open-label, phase 3, randomized, non-inferiority study aimed to investigate the effect on disease-free survival of adjuvant chemotherapy with oxaliplatin plus S-1 compared with adjuvant chemotherapy with docetaxel plus S-1 after D2 gastrectomy in patients with stage III gastric cancer.
Participants needed: 387
Trial details
Phase: Phase 3Age: 18-80Biological sex: AllType: InterventionalSponsor: Ruijin HospitalUpdated: Jan 26, 2026Locations: 5
Eligibility criteria
age 18 to 80 years old, male and female [+8]
other primary malignancies, except for cured skin tumors or cervical carcinoma i... [+6]